Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference
October 11, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR®...
Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions
September 29, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR®...
Selecta Biosciences to Participate in Upcoming Investor Conferences
September 12, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...
Selecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...
Selecta Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
August 04, 2022 07:30 ET
|
Selecta Biosciences, Inc.
– Completed enrollment of DISSOLVE II, triggering a $10 million milestone payment obligation from Swedish Orphan Biovitrum AB (publ.) (Sobi); DISSOLVE I & II studies remain on track for joint...
Selecta Biosciences to Participate in Upcoming Investor Conferences
August 01, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...
Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update
July 28, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...
Selecta Biosciences to Participate at the Guggenheim I&I Spotlight Series – Treg-based Therapies Conference
July 06, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...
Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates
June 13, 2022 07:30 ET
|
Selecta Biosciences, Inc.
-Sarepta extends Research License and Option Agreement for ImmTOR® in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies- -Selecta to receive a $2 million payment from Sarepta...
Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference
May 17, 2022 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic...